Recent discoveries have increased our comprehension of the molecular signaling events critical for melanoma development and progression. Many oncogenes driving melanoma have been identified, and most of them exert their oncogenic effects through the activation of the RAF/MEK/ERK mitogen-activated protein kinase (MAPK) pathway. The c-Jun N-terminal kinase (JNK) and p38 MAPK pathways are also important in melanoma, but their precise role is not clear yet. This review summarizes our current knowledge on the role of the three main MAPK pathways, extracellular regulated kinase (ERK), JNK, and p38, and their impact on melanoma biology. Although the results obtained with BRAF inhibitors in melanoma patients are impressive, several mechanisms of ac...
Despite the disappointing results of early clinical studies, targeting the BRAF ⁄ MEK⁄ extracellular...
BACKGROUND:Kinase inhibition in the mitogen activated protein kinase (MAPK) pathway is a standard th...
Although advances in cytotoxic treatments have been obtained in several neoplasias, in metastatic me...
BRAF and MEK inhibitors, alone or in combination, are highly active in the 40% of patients with BRAF...
The mitogen-activated protein kinase (MAPK) pathway is a cascade of serine-threonine kinases involve...
The discovery of the BRAFV600E mutation led to the development of vemurafenib (PLX4032), a selective...
Treatment of BRAF-mutant metastatic melanoma with mitogen-activated protein kinase (MAPK) pathway ta...
Melanoma is a highly aggressive tumor with a strong dependence on intracellular signaling pathways. ...
BACKGROUND: Several studies suggest that melanoma may be resistant to treatment because of resistanc...
ABSTRACT Most melanomas harbor oncogenic BRAF V600 mutations, which constitutively acti-vate the MAP...
Understanding regulatory pathways involved in melanoma development and progression has advanced sign...
Despite years of research, there has been little improvement in survival for patients with dissemina...
The discovery of the role of the RAS/RAF/MEK/ERK pathway in melanomagenesis and its progression have...
Malignant melanoma is an aggressive skin tumour with increasing incidence and, in advanced stages, l...
About 50% of metastatic melanomas harbor BRAF V600 mutations, most commonly a V600E substitution, wh...
Despite the disappointing results of early clinical studies, targeting the BRAF ⁄ MEK⁄ extracellular...
BACKGROUND:Kinase inhibition in the mitogen activated protein kinase (MAPK) pathway is a standard th...
Although advances in cytotoxic treatments have been obtained in several neoplasias, in metastatic me...
BRAF and MEK inhibitors, alone or in combination, are highly active in the 40% of patients with BRAF...
The mitogen-activated protein kinase (MAPK) pathway is a cascade of serine-threonine kinases involve...
The discovery of the BRAFV600E mutation led to the development of vemurafenib (PLX4032), a selective...
Treatment of BRAF-mutant metastatic melanoma with mitogen-activated protein kinase (MAPK) pathway ta...
Melanoma is a highly aggressive tumor with a strong dependence on intracellular signaling pathways. ...
BACKGROUND: Several studies suggest that melanoma may be resistant to treatment because of resistanc...
ABSTRACT Most melanomas harbor oncogenic BRAF V600 mutations, which constitutively acti-vate the MAP...
Understanding regulatory pathways involved in melanoma development and progression has advanced sign...
Despite years of research, there has been little improvement in survival for patients with dissemina...
The discovery of the role of the RAS/RAF/MEK/ERK pathway in melanomagenesis and its progression have...
Malignant melanoma is an aggressive skin tumour with increasing incidence and, in advanced stages, l...
About 50% of metastatic melanomas harbor BRAF V600 mutations, most commonly a V600E substitution, wh...
Despite the disappointing results of early clinical studies, targeting the BRAF ⁄ MEK⁄ extracellular...
BACKGROUND:Kinase inhibition in the mitogen activated protein kinase (MAPK) pathway is a standard th...
Although advances in cytotoxic treatments have been obtained in several neoplasias, in metastatic me...